Thelansis

Hepatocellular Carcinoma (HCC) Epidemiology Insights Thelansis’s “Hepatocellular Carcinoma (HCC) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies. Key business questions answered: 20-year historical and forecast data (2020–2040) Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes) Granular patient population coverage by year and geography Detailed segmentation by age, gender, subpopulations, comorbidities, li...

Hepatocellular Carcinoma (HCC) Epidemiology Insights Thelansis’s  “Hepatocellular Carcinoma (HCC) Epidemiology Insights and Forecast Report – 2020 To 2040″  provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies . Hepatocellular Carcinoma (HCC) Overview Hepatocellular carcinoma (HCC) is the most common primary liver cancer, arising from hepatocytes and typically developing in the setting of chronic liver disease such as cirrhosis due to chronic hepatitis B or C infection, alcohol use, or non‑alcoholic steatohepatitis, with addition...